Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031121 · ClinicalTrials.gov registry record
Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 240
- Enrollment target
NCT01031121: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01031121 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031121 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 240 participants
- Enrollment target
Study Summary
Background: * Self-report and biochemical verification are used to determine smoking status in treatment trials and clinical research. Each method has merits and limitations that make it appropriate for particular situations. Participants who feel social pressure to report tobacco abstinence may provide unreliable self-reporting results. Biochemical verification using breath carbon monoxide (CO) is a more reliable indicator, but several biological and environmental factors (including exposure to secondhand smoke) can affect the sensitivity and specificity of breath CO measurement. * An ideal biomarker of smoking status is cotinine, the major metabolite of nicotine. Cotinine levels found in blood, urine, and saliva can be used to distinguish between smokers and nonsmokers, as well as between light and heavy smokers. Researchers are interested in using cotinine assessments to develop suitable breath CO cutoff levels to categorize different types of smokers and nonsmokers for use in future research. Objectives: \- To determine a breath carbon monoxide (CO) cutoff level that optimally discriminates between heavy and light smokers and nonsmokers who are and who are not exposed to environmental tobacco smoke. Eligibility: * Individuals between 18 and 64 years of age who fall into one of the following groups: * current smokers reporting more than 10 cigarettes per day for at least 6 months * current smokers reporting 10 or fewer cigarettes per day for at least 6 months * nonsmokers reporting regular environmental exposure to tobacco smoke * nonsmokers reporting limited or no exposure to tobacco smoke Design: * The study will involve a single outpatient session. * Participants will provide breath CO, urine, and saliva samples, and will complete several smoking-related questionnaires on smoking history, current craving levels, and perceived level of nicotine dependence.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2009-06-08 |
| Est. Completion | 2010-10-22 |
What the finished NCT01031121 record still lists
NCT01031121 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01031121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01031121 about?
NCT01031121 is a clinical study titled "Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers". Background: * Self-report and biochemical verification are used to determine smoking status in treatment trials and clinical research. Each method has merits and limitations that make it appropriate for particular situations. Participants who feel social pressure to report tobacco abstinence may pr...
What is the current status of trial NCT01031121?
This trial is currently completed. The enrollment target is 240 participants. The study started on 2009-06-08. Estimated completion is 2010-10-22.
Who is sponsoring clinical trial NCT01031121?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI